Abstract
Background Hypertrophic cardiomyopathy (HCM) is an important cause of sudden cardiac death associated with heterogeneous phenotypes but there is no systematic framework for classifying morphology or assessing associated risks. Here we quantitatively survey genotype-phenotype associations in HCM to derive a data-driven taxonomy of disease expression.
Methods We enrolled 436 HCM patients (median age 60 years; 28.8% women) with clinical, genetic and imaging data. An independent cohort of 60 HCM patients from Singapore (median age 59 years; 11% women) and a reference population from UK Biobank (n = 16,691, mean age 55 years; 52.5% women) were also recruited. We used machine learning to analyse the three-dimensional structure of the left ventricle from cardiac magnetic resonance imaging and build a tree-based classification of HCM phenotypes. Genotype and mortality risk distributions were projected on the tree.
Results Carriers of pathogenic or likely pathogenic variants for HCM (P/LP) variants had lower left ventricular mass, but greater basal septal hypertrophy, with reduced lifespan (mean follow-up 9.9 years) compared to genotype negative individuals (hazard ratio: 2.66; 95% confidence interval [CI]: 1.42-4.96; P < 0.002). Four main phenotypic branches were identified using unsupervised learning of three-dimensional shape: 1) non-sarcomeric hypertrophy with co-existing hypertension; 2) diffuse and basal asymmetric hypertrophy associated with outflow tract obstruction; 3) isolated basal hypertrophy; 4) milder non-obstructive hypertrophy enriched for familial sarcomeric HCM (odds ratio for P/LP variants: 2.18 [95% CI: 1.93-2.28, P = 0.0001]). Polygenic risk for HCM was also associated with different patterns and degrees of disease expression. The model was generalisable to an independent cohort (trustworthiness M1: 0.86-0.88).
Conclusions We report a data-driven taxonomy of HCM for identifying groups of patients with similar morphology while preserving a continuum of disease severity, genetic risk and outcomes. This approach will be of value in understanding the causes and consequences of disease diversity.
Competing Interest Statement
J.S.W. has consulted for MyoKardia, Inc., Foresite Labs, and Pfizer, and receives research support from Bristol Myers Squibb outside the submitted work. D.P.OR. has consulted for Bayer AG and Bristol Myers Squibb, and also receives research support from Bayer AG outside the submitted work. The remaining authors have nothing to disclose.
Funding Statement
The study was supported by the National Institute for Health Research (NIHR) Royal Brompton Cardiovascular Biomedical Research Unit; Medical Research Council (MC_UP_1605/13); National Institute for Health Research (NIHR) Imperial College Biomedical Research Centre; the British Heart Foundation (RG/19/6/34387, RE/18/4/34215, FS/IPBSRF/22/27059, FS/ICRF/21/26019); Engineering and Physical Sciences Research Council (EP/W01842X/1); Academy of Medical Sciences (SGL015/1006); Mason Medical Research Trust; Sir Jules Thorn Charitable Trust [21JTA]; the NHLI Foundation Royston Centre for Cardiomyopathy Research; and the Rosetrees Trust.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided written informed consent and the study was approved by the National Research Ethics Service, UK (19/SC/0257, 11/NW/0382); and Singhealth Centralised Institutional Review Board (2020/2353) and the Singhealth Biobank Research Scientific Advisory Executive Committee (SBRSA 2019/001v1), Singapore.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Joint first authors.
Figure 3 updated to include polygenic score. Authors and affiliations updated.
Data Availability
The code used in the study is available on GitHub. Population data is available from UK Biobank.
